Altmetric

Prospective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancer

File Description SizeFormat 
180105 Butt A IJC.pdfAccepted version287.18 kBAdobe PDFView/Open
Title: Prospective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancer
Authors: Butt, J
Jenab, M
Willhauck-Fleckenstein, M
Michel, A
Pawlita, M
Kyro, C
Tjønneland, A
Boutron-Ruault, M-C
Carbonnel, F
Severi, G
Kaaks, R
Kuhn, T
Boeing, H
Trichopoulou, A
La Vecchia, C
Karakatsani, A
Panico, S
Tumino, R
Agnoli, C
Palli, D
Sacerdote, C
Bueno-de-Mesquita, B
Weiderpass, E
Sánchez, M-J
Bonet, C
Murphy, N
Freisling, H
Riboli, E
Tsilidis, K
Aune, D
Waterboer, T
Hughes, D
Item Type: Journal Article
Abstract: The gut microbiome is increasingly implicated in colorectal cancer (CRC) development. A subgroup of patients diagnosed with CRC show high antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG). However, it is unclear whether the association is also present pre‐diagnostically. We assessed the association of antibody responses to SGG proteins in pre‐diagnostic serum samples with CRC risk in a case–control study nested within a prospective cohort. Pre‐diagnostic serum samples from 485 first incident CRC cases (mean time between blood draw and diagnosis 3.4 years) and 485 matched controls in the European Prospective Investigation into Nutrition and Cancer (EPIC) study were analyzed for antibody responses to 11 SGG proteins using multiplex serology. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable conditional logistic regression models. Antibody positivity for any of the 11 SGG proteins was significantly associated with CRC risk with 56% positive controls compared to 63% positive cases (OR: 1.36, 95% CI: 1.04–1.77). Positivity for two or more proteins of a previously identified SGG 6‐marker panel with greater CRC‐specificity was also observed among 9% of controls compared to 17% of CRC cases, corresponding to a significantly increased CRC risk (OR: 2.17, 95% CI: 1.44–3.27). In this prospective nested case–control study, we observed a positive association between antibody responses to SGG and CRC development in serum samples taken before evident disease onset. Further work is required to establish the possibly etiological significance of these observations and whether SGG serology may be applicable for CRC risk stratification.
Issue Date: 15-Jul-2018
Date of Acceptance: 5-Jan-2018
URI: http://hdl.handle.net/10044/1/56441
DOI: https://dx.doi.org/10.1002/ijc.31283
ISSN: 0020-7136
Publisher: Wiley
Start Page: 245
End Page: 252
Journal / Book Title: International Journal of Cancer
Volume: 143
Issue: 2
Copyright Statement: © 2018 UICC. This is the accepted version of the following article, which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.31283
Sponsor/Funder: Commission of the European Communities
Funder's Grant Number: SP23-CT-2005-006438
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
colorectal neoplasms
Streptococcus gallolyticus
bacterial serology
antibodies
prospective cohort
SUBSPECIES GALLOLYTICUS
ASSOCIATION
BOVIS
ENDOCARDITIS
BACTEREMIA
SEROLOGY
DISEASE
COHORT
COLON
1112 Oncology And Carcinogenesis
Oncology & Carcinogenesis
Publication Status: Published
Online Publication Date: 2018-01-29
Appears in Collections:Faculty of Medicine
Epidemiology, Public Health and Primary Care



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons